CIK 0001650664
- Non-accelerated filer
- Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464097528
- Phone
- +1 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Technology Officer sold 3,000 shares at $24.50 ($73,500)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 10,200 shares at $23.94 ($244,188)
- 4 Open-market sale Chief Technology Officer sold 3,000 shares at $20.42 ($61,260)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Financial Officer sold 6,895 shares at $21.39 ($147,484)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Technology Officer sold 7,000 shares at an average $26.36 ($184,540)
- 4 Open-market sale President and CEO sold 12,000 shares at $25.27 ($303,240)
- 4 Open-market sale Chief Financial Officer sold 7,000 shares at $22.48 ($157,360)
- 4/A Exercise or conversion Chief Financial Officer acquired 5,284 shares (option exercise)
- 4/A Exercise or conversion Chief Financial Officer acquired 6,000 shares (option exercise)
- 4 Open-market sale Chief Technology Officer sold 7,000 shares at an average $27.61 ($193,303)
- 4 Derivatives Options or other derivatives
Page 11 of 18 · 351 filings